[Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: guidelines of the SFGM-TC].

Date publication

août 2014

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana

Tous les auteurs :
Guillaume T, Porcheron S, Audat F, Bancillon N, Berceanu A, Charbonnier A, Dulery R, Edy N, El Cheikh J, Hermet E, Maurer N, Paul F, Konopacki-Potet J, Turlure P, Wallart A, Boulanger F, Dhedin N, Suarez F, Yakoub-Agha I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/24996843

Résumé

In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) set up the fourth annual series of workshops which brought together practitioners from all member centers and took place in September 2013 in Lille. Here, we report our recommendations regarding the use of donor lymphocyte injection (DLI) in the prophylactic, pre-emptive and curative settings. This work has been limited to allogeneic stem cell transplantations from an HLA-matched (10/10) or -one antigen-mismatched (9/10) donor.

Référence

Pathol Biol (Paris). 2014 Aug;62(4):193-6